Novavax Stock News

Novavax officials said they''re going "full blast" for 2022 plans for the company''s Covid vaccine after a busy final quarter of 2021.

If there’s one thing Novavax executives wanted to push across in the company’s 2021 Q4 earnings call Monday, it’s that, after months of struggles, it is in a position to manufacture 2 billion doses of its Covid-19 vaccine. CEO Stanley Erck, CMO Filip Dubovsky and chief business and commercial officer

The COVID-19 vaccine developed by Pfizer and German partner BioNTech is much less effective in preventing infection in children aged 5 to 11 than in older people, according to a new data set from h

Investors like the vaccine maker's 2022 revenue outlook.

Novavax (NVAX) reports a wider-than-expected loss for the fourth quarter of 2021. Also, revenues miss estimates. Its shares decline in after-market trading following the announcement.

It's not likely, but it could still end up being a good investment.

In the last trading session, 4.15 million Novavax Inc. (NASDAQ:NVAX) shares changed hands as the company’s beta touched 1.42. With the company’s per share price at $83.37 changed hands at $1.74 or 2.13% during last session, the market valuation stood at $6.17B. NVAX’s last price was a discount, traded about -233.21% off its 52-week high … Novavax Inc. (NASDAQ: NVAX) Stock: Performance and Outlook Read More »

Novavax''s highly anticipated Covid vaccine lagged sales expectations in its first quarter on the market, but NVAX stock reversed on Tuesday.

Novavax Climbs as COVID-19 Vaccine Sales Finally Seen Coming Through

Shares of Novavax Inc. were down 6.7% in premarket trading on Tuesday, the day after the company fell short of revenue expectations for the fourth quarter of 2021. Novavax on Monday reported $222.2 million in revenue in the fourth quarter of 2021. The FactSet consensus was $331.8 million. The company''s protein-based COVID-19 vaccine is its only authorized or approved therapy; it recently received authorization in several regions, including the European Union, New Zealand, and the U.K. (The shot is currently under review in the U.S.) Novavax''s stock has tumbled 65.3% over the past year, while the broader S&P 500 is up 14.4%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Lucid cut its 2022 vehicle-production target; AMC Entertainment is due to report results.

This article was originally published on TipRanks.com Biotech stock Novavax, Inc. The post Novavax Posts Larger-than-Expected Q4 Loss; Shares Slide appeared first on Smarter Analyst .

Highlights Novavax, Inc. was working on its plan to introduce a single injection that protects against Covid-19 and seasonal flu. Novavax informed that it expects to launch the combo vaccine later this year. Many scientists have predicted that the Covid-19 booster dose will be required each year; therefore, pharmaceuticals companies are working on combing seasonal flu, and Covid-19 does. Clinical stage company, Novavax, Inc. ( NYSE:NVAX ) was already working its plan to introduce a single injection that protects against Covid-19 and seasonal flu. Novavax shared an update that it expects to launch a new trial of the combo vaccine later this year. Must read : Australian kids aged 6-11 can now get Moderna’s COVID-19 vaccine In the earnings call on Tuesday, Stanley Erck, CEO of Novavax, informed that it has brought its vaccine to the market. He also announced that the company had gained authorisation in 38 countries. Novavax work on the Covid-flu combo Since the beginning of the pandemic, Novavax has been working on developing the Covid-flu combo vaccine.

Wellington, March 1 (IANS) New Zealanders will soon be able to access a third type of Novavax vaccine following the government’s confirmation. Covid Response Minister Chris Hipkins said on Tuesday that Novavax will soon be available to New Zealanders aged 18 and over, Xinhua news agency reported. “Novavax is a protein-based Covid vaccine and while […] The post New Zealand approves 3rd Covid vaccine Novavax appeared first on Buziness Bytes .

WELLINGTON, March 1 (Xinhua) -- New Zealanders will soon be able to access a third type of Novavax vaccine following the government''s confirmation on Monday. COVID-19 Response Minister Chris Hipkins said on Tuesday that Novavax will soon be available to New Zealanders aged 18 and over. "Novavax is a protein-based COVID-19 vaccine and while the Pfizer COVID-19 vaccine remains the preferred vaccine of most